The present investigation deals with the evaluation for the first time of the in vitro antimicrobial and α-glucosidase inhibitory potential of a series of fifteen enantiopure cycloalkylglycines using agar well diffusion and spectrophotometric methods, respectively.
The obtained results were compared to the positive controls. The antimicrobial results revealed that all compounds exerted strongly inhibitory activity, especially against Gram(+) bacterial strains with the most potent activity was ascribed to α-γ-hydroxy-α-amino acids 11-14 (MIC=1.58-12.50 mg/mL, MBC=3.17-100 mg/mL, MFC=6.25-50 mg/mL) followed by both isoxazolidines 5-9 (MIC=1.58-12.50 mg/mL, MBC=6.25-100 mg/mL, MFC=25-100 mg/mL) and isoxazine 10 (MIC=3.17-12.50 mg/mL, MBC=3.17-50 mg/mL, MFC=25-50 mg/mL) compounds, and slightly with α-amino-γ-lactones series 1-4 (MIC=3.17-25 mg/mL, MBC=6.25-100 mg/mL, MFC=25-100 mg/mL), respectively. All derivatives exhibited potent α-glucosidase inhibitory activity with compound 10 (IC50 = 30.1±0.6 μM) was found to be the most active. Drug-likeness and pharmacokinetic profiles have been also predicted. The in silico results indicate that all derivatives showed resemblance with several parameters of the antimicrobial standards, especially in terms of molecular property, bioavailability, lipophilicity, medicinal chemistry and enzymatic inhibitory effects as well as they agree with the different drug discovery rules such as Lipinski (Pfizer), Ghose (Amgen), Veber (GSK), Egan (Pharmacia), and Muegge (Bayer) displaying higher drug likeness behavior.
Key words: cycloalkylglycines, in vitro antimicrobial, α-glucosidase inhibitory potential, drug-likeness, medicinal chemistry.
|
